ELC-201 / Elicera Therap - LARVOL DELTA

Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company’s oncolytic virus candidates, ELC-100 and ELC-201 (Elicera Press Release) - "Elicera Therapeutics...announces that it has entered into a Material Transfer Agreement (MTA) with University Hospital Tübingen in Germany. Under the agreement, the company’s oncolytic virus candidates ELC-100 and ELC-201 will be included in tests aimed at developing a new type of companion diagnostic to predict the potential success of a novel neuroendocrine neoplasm (NEN) therapy, immuno-virotherapy....According to Elicera’s MTA with University Hospital Tübingen, the hospital, under the leadership of Professor Ulrich M. Lauer and Dr. Linus Kloker, will receive access to ELC-100 and ELC-201 to conduct testing aimed at developing a new type of companion diagnostic. The purpose of this diagnostic is to predict the potential success of immuno-virotherapy before initiating treatment with this new combination for NEN."

Licensing / partnership • Neuroendocrine Tumor

Elicera Therapeutics enters a preclinical collaboration agreement with China Medical University for the development of ELC-201 (Elicera Press Release) - "Elicera Therapeutics AB...announces today that the company has entered a research collaboration with Fourth Affiliated Hospital of China Medical University (CMU4). Through this agreement, the efficacy of the oncolytic virus ELC-201 will be evaluated in preclinical proof-of-concept studies across multiple solid tumor indications. According to the collaboration agreement with CMU4, the university, under the leadership of Dr. Li Xuexin, Director of the Biomedical Innovation Center, will have access to ELC-201 to conduct preclinical proof-of-concept studies in organoids - cell collections that have an organ-like structure - derived from cancer patients. The studies aim to evaluate both the treatment efficacy and the safety profile of ELC-201 in several solid tumor types, including pancreatic cancer (PDAC), gastric cancer (GI), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), and non-muscle invasive bladder cancer (NMBIC)."

Licensing / partnership • Preclinical • Bladder Cancer • Gastric Cancer • Pancreatic Ductal Adenocarcinoma • Renal Cell Carcinoma • Triple Negative Breast Cancer

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023 (Elicera Press Release) - "The clinical trial, which we also call the CARMA study, is intended to evaluate the safety and efficacy of a dose of CD20-targeted CAR T-cells...The approval is conditional on Elicera conducting certain further validations of its GMP process, which was previously was expected to be completed and given final approval during the third quarter of the year but which we now, after additional dialogue with the Agency, is instead expected to be completed in the fourth quarter of the year. First patient is expected to be treated in the beginning of 2024....We have made progress in our ongoing clinical phase I/IIa study with our oncolytic virus, ELC-100, in the treatment of neuroendocrine tumors and will shortly treat patient number 11. Thus, we only have one patient left to treat in the dose escalation phase, which we expect to be able to do by the turn of the year."

New P1/2 trial • Trial status • Hematological Malignancies • Lymphoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023 (Elicera Press Release) - "The objective for both ELC-201 and ELC-401 during the year is to produce clinical development plans, including trial design and costs for the forthcoming Phase I/II trials, and thereafter to decide how the programs should best be advanced and financed – by Elicera alone or potentially together with a partner."

Clinical protocol • Commercial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston (Cision) - P1/2 | N=35 | RADNET (NCT02749331) | "Elicera Therapeutics AB..announced that two of a total of eight patients so far fully treated and evaluated in the ongoing phase I/IIa study, which evaluates the oncolytic virus ELC-100 for the treatment of neuroendocrine tumors, have shown signs of clinical activity by reducing the size of some metastases....Reporting of safety data for the third patient cohort is expected to occur in the first quarter of 2023. So far, no dose-limiting adverse events have been reported in the second cohort. Full efficacy reporting from the ELC-100 study is expected when the study is fully completed, which is estimated to occur in 2023 at the earliest....Besides the additional signals of clinical activity from the ELC-100 study, proof-of-concept data from the company's preclinical studies for its second oncolytic virus ELC-201, which confirms the virus' mechanism of action, will also be presented at the conference."

P1/2 data • Preclinical • Neuroendocrine Tumor • Oncology • Solid Tumor

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201 (Market Screener) - “Elicera Therapeutics AB…announced today that it has signed an agreement with Baylor College of Medicine (BCM), Center for Cell & Gene Therapy regulating contract manufacturing of ELC-201, the company's next generation oncolytic virus armed with Elicera's fully developed iTANK-platform for a multi-targeted attack on cancer.”

Licensing / partnership • Oncology

"Elicera Therapeutics sluter avtal med Baylor College of Medicine för kontraktstillverkning av nästa generations onkolytiska virus, ELC-201 https://t.co/UVqhXv4Frg" (@CisionNews)